Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Want to cut your energy bills? Here’s how five experts are doing it 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
DURHAM, N.C., March 09, 2016 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer, will participate in the 27th Annual Cancer Progress Conference by Defined Health being held in New York City. Dr. Schreiber will serve as a speaker on a panel entitled “Immuno-Oncology I: Attacking Cancer Antigens – Exploiting off-the-Shelf and Personalized Vaccines and Triggering of Immunogenic Cell Death,” which takes place today at 9:15 a.m. Eastern Time.
Cancer Progress is an oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives. The conference spans over two days, encompassing interactive dialogue among industry professionals. For more information regarding the conference and agenda, please visit www.cancerprogressbydh.com.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
